Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new PET scan pinpoint the cause of Cushing's syndrome?

NCT ID NCT07350707

Recruiting now Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of PET scan using a tracer called 68Ga-Pentixafor to help doctors tell apart the two main types of Cushing's syndrome (ACTH-dependent vs. ACTH-independent) and find the source of the problem. Researchers will enroll 160 adults with suspected or confirmed Cushing's syndrome. If it works, this scan could make diagnosis more accurate and reduce the need for multiple tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
68Ga-Pentixafor (a radioactive tracer for PET scans)
What this could lead to
If successful, this imaging method could help doctors more accurately diagnose the type of Cushing's syndrome and locate hard-to-find tumors, leading to better treatment decisions.
What could go wrong
This is an early-phase study (Phase 1/2) with only 160 participants. The new scan may not prove more accurate than existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUSHING'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING'S SYNDROME

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.